Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
01:10pm, Monday, 15'th Dec 2025
Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ: SNY). The new agreement is built on the existing relationship between the two companie
Dren Bio to collaborate with Sanofi to develop autoimmune disease therapies for up to $1.7 billion
08:21am, Monday, 15'th Dec 2025
Dren Bio, a private biotech company, said on Monday it has entered into a strategic collaboration with Sanofi to develop therapies for autoimmune diseases in a deal worth up to $1.7 billion.
Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
08:05am, Monday, 15'th Dec 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)--Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy.
Sanofi shares slide as FDA delays MS drug decision and late-stage trial disappoints
05:48am, Monday, 15'th Dec 2025
Shares of French pharmaceutical group Sanofi fell sharply on Monday after the company flagged another delay to a US regulatory decision for its experimental multiple sclerosis drug tolebrutinib and re
Cullen Capital Management LLC Acquires 36,714 Shares of Sanofi $SNY
05:11am, Monday, 15'th Dec 2025
Cullen Capital Management LLC raised its holdings in shares of Sanofi (NASDAQ: SNY) by 9.2% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commissio
Sanofi stock slumps after two setbacks on multiple-sclerosis drug
04:43am, Monday, 15'th Dec 2025
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won't be completed by the end of the year and that a trial for a different form
Sanofi flags delay in FDA's decision on tolebrutinib, shares fall
03:49am, Monday, 15'th Dec 2025
French pharmaceutical group Sanofi said on Monday the U.S. Food and Drug Administration's decision on its investigative drug to treat multiple sclerosis was expected to be delayed until the first quar
Sanofi Multiple Sclerosis Drug Hit by Double Setback
01:56am, Monday, 15'th Dec 2025
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of the disease didn't hit its main goal.
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
01:05am, Monday, 15'th Dec 2025
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated regu
Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs
01:11pm, Thursday, 11'th Dec 2025
The National Medical Products Administration (NMPA) in China has approved Sanofi SA's (NASDAQ: SNY) two medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplaci
Sanofi's Bleeding-Disorder Treatments Get Approval in China
01:42am, Thursday, 11'th Dec 2025
Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.
Press Release: Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases
01:00am, Thursday, 11'th Dec 2025
Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six inj
SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimm
Market Today: Fed Cut Looms, Nvidia's China Shift, Target's SoHo Push, OpenAI Taps Slack CEO
05:34pm, Tuesday, 09'th Dec 2025
Stock News Fed set for âhawkish cut': Goldman Sachs (GS) and other Wall Street desks expect the Federal Reserve to deliver a third straight 25 bps rate cut wh
